The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Study participants have already been dosed and a plasma sample analysis is being conducted. BioDelivery intends to present results from the study before the end of September 2012. According to an ...

BioDelivery Sciences International, Inc. shares are dropping after the company reported that it's borrowed $20.7 million. By Todd Campbell – Updated Jun 1, 2015 at 1:02PM EST Although we don't believe ...

All cash flow is not created equal. Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because ...

BioDelivery Sciences International, Inc.BDSI and its partner Endo International plc ENDP were up 8.3% and 4.2%, respectively, after the FDA approved Belbuca (buprenorphine HCL buccal film) for the ...

Under the terms of its commercialization agreement with Meda, BioDelivery Sciences will receive an aggregate of approximately $27 million in milestone payments. The first is based upon FDA approval of ...

BioDelivery Sciences International, Inc. BDSI is focused on the development and commercialization of treatments in the areas of pain management and drug addiction. The company’s portfolio consists of ...

Shares of BioDelivery Sciences International Inc. blasted 51.7% higher to pace all premarket gainers Monday, after the specialty pharmaceutical company with a portfolio of pain and neurology products ...

(Reuters) - BioDelivery Sciences International Inc said the U.S. Food and Drug Administration had approved its opioid treatment for chronic pain, sending the drugmaker's shares up 23 percent in ...